EP0188040B1
(de)
*
|
1985-01-11 |
1991-08-14 |
Abbott Laboratories Limited |
Feste Zubereitung mit langsamer Freisetzung
|
WO1987004077A1
(en)
*
|
1986-01-03 |
1987-07-16 |
The University Of Melbourne |
Gastro-oesophageal reflux composition
|
CA1302659C
(en)
*
|
1986-10-24 |
1992-06-09 |
Hans-Peter K. Gribi |
Dental impression material
|
EP0275336A1
(de)
*
|
1987-01-20 |
1988-07-27 |
Knoll Ag |
Arzneimittelzubereitung mit protahierender Wirkung
|
US5064736A
(en)
*
|
1988-03-23 |
1991-11-12 |
Olin Corporation |
Electrostatic method for multicolor imaging from a single toner bath
|
DE4002281A1
(de)
*
|
1990-01-26 |
1991-08-01 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches system mit dem wirkstoff tulobuterol
|
NL9002008A
(nl)
|
1990-09-12 |
1992-04-01 |
Stichting Centr Diergeneeskund |
Recombinant dna en rna en daarvan afgeleide produkten.
|
FR2676364B1
(fr)
*
|
1991-05-17 |
1993-09-10 |
Lafon Labor |
Composition pharmaceutique a base de derives d'aminobutanone.
|
US5368862A
(en)
*
|
1991-12-18 |
1994-11-29 |
Merck & Co., Inc. |
Sustained release tablets containing alginate
|
US5411746A
(en)
*
|
1993-02-24 |
1995-05-02 |
Warner-Jenkinson Company, Inc. |
Dye compositions and methods for film coating tablets and the like
|
US5670169A
(en)
*
|
1993-12-20 |
1997-09-23 |
E.R. Squibb & Sons, Inc. |
Wound hydrating gel with novel preservative system and low cytotoxicity
|
US6692766B1
(en)
*
|
1994-06-15 |
2004-02-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Controlled release oral drug delivery system
|
DE4443358A1
(de)
*
|
1994-12-06 |
1996-06-13 |
Basf Ag |
Depot-Arzneimittel
|
US5879712A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sri International |
Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
|
US5811126A
(en)
*
|
1995-10-02 |
1998-09-22 |
Euro-Celtique, S.A. |
Controlled release matrix for pharmaceuticals
|
US5705190A
(en)
*
|
1995-12-19 |
1998-01-06 |
Abbott Laboratories |
Controlled release formulation for poorly soluble basic drugs
|
US20050064033A1
(en)
*
|
1997-04-11 |
2005-03-24 |
Notario Gerard F. |
Extended release formulations of erythromycin derivatives
|
US6010718A
(en)
*
|
1997-04-11 |
2000-01-04 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
US6551616B1
(en)
|
1997-04-11 |
2003-04-22 |
Abbott Laboratories |
Extended release formulations of erythromycin derivatives
|
SI20108B
(en)
*
|
1997-06-11 |
2001-12-31 |
Abbott Lab |
A controlled release formulation for poorly soluble basic drugs
|
IN186245B
(de)
|
1997-09-19 |
2001-07-14 |
Ranbaxy Lab Ltd |
|
US7022683B1
(en)
*
|
1998-05-13 |
2006-04-04 |
Carrington Laboratories, Inc. |
Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
|
BG65116B1
(bg)
*
|
2000-01-06 |
2007-03-30 |
Abbott Laboratories |
Лекарствена форма с контролирано освобождаване наслабо разтворими основни лекарствени средства
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
EP1313486A1
(de)
*
|
2000-02-29 |
2003-05-28 |
Teva Pharmaceutical Industries Ltd. |
Verfahren zur herstellung des clarithromycins und eines clarithromycin-zwischenprodukt; clarithromycin wesentlich frei von oxime; und pharmazeutische zusammensetzung die sie enthalten
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US6541014B2
(en)
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US7494669B2
(en)
*
|
2001-02-28 |
2009-02-24 |
Carrington Laboratories, Inc. |
Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
|
US6777000B2
(en)
*
|
2001-02-28 |
2004-08-17 |
Carrington Laboratories, Inc. |
In-situ gel formation of pectin
|
US6642276B2
(en)
*
|
2001-10-01 |
2003-11-04 |
M/S Ind-Swift Limited |
Controlled release macrolide pharmaceutical formulations
|
CA2465405A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Wockhardt Limited |
Controlled release compositions for macrolide antimicrobial agents
|
US6602911B2
(en)
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
WO2003105810A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Andrx Corporation |
Pharmaceutical compositions for drugs having ph-dependentsolubility
|
SI21300A
(sl)
*
|
2002-10-08 |
2004-04-30 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Farmacevtske formulacije z alginati
|
US20100092562A1
(en)
*
|
2002-11-26 |
2010-04-15 |
Hollenbeck R Gary |
Sustained-release drug delivery compositions and methods
|
GB0230034D0
(en)
*
|
2002-12-23 |
2003-01-29 |
Biochemie Gmbh |
Organic compounds
|
US7063862B2
(en)
*
|
2003-06-03 |
2006-06-20 |
Biokey, Inc. |
Pharmaceutical composition and method for treating
|
CA2529746C
(en)
*
|
2003-06-16 |
2010-08-03 |
Andrx Pharmaceuticals, Llc |
Oral extended-release composition
|
US20050053658A1
(en)
*
|
2003-09-09 |
2005-03-10 |
Venkatesh Gopi M. |
Extended release systems for macrolide antibiotics
|
EP1648418A4
(de)
|
2003-07-21 |
2011-11-16 |
Middlebrook Pharmaceuticals Inc |
Antibiotisches produkt, seine verwendung und formulierung
|
CA2533292C
(en)
|
2003-07-21 |
2013-12-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
AU2004258949B2
(en)
|
2003-07-21 |
2011-02-10 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
JP2007502296A
(ja)
|
2003-08-11 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
ロバストペレット
|
AU2004264356B2
(en)
|
2003-08-12 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
US8246996B2
(en)
|
2003-08-29 |
2012-08-21 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
US8460710B2
(en)
|
2003-09-15 |
2013-06-11 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
US8168228B2
(en)
*
|
2003-10-17 |
2012-05-01 |
Sandoz Ag |
Antibiotic clarithromycin micropellet compositions
|
US20050084540A1
(en)
*
|
2003-10-17 |
2005-04-21 |
Indranil Nandi |
Taste masking antibiotic composition
|
US20050101547A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Sadatrezaei Mohsen |
Stabilized azithromycin composition
|
US7943585B2
(en)
|
2003-12-22 |
2011-05-17 |
Sandoz, Inc. |
Extended release antibiotic composition
|
WO2005074598A2
(en)
|
2004-01-30 |
2005-08-18 |
Johns Hopkins University |
Nitroxyl progenitor compounds and methods of use
|
US20050260263A1
(en)
*
|
2004-05-18 |
2005-11-24 |
Panion & Bf Biotech Inc. |
Sustained release formulation for sparingly soluble main drugs
|
EP1765336A4
(de)
|
2004-06-25 |
2010-03-10 |
Univ Johns Hopkins |
Angiogenesehemmer
|
EP1771158A4
(de)
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
Tablette für pulsierte abgabe
|
US20070020333A1
(en)
*
|
2005-07-20 |
2007-01-25 |
Chin-Chih Chiang |
Controlled release of hypnotic agents
|
CA2617150C
(en)
*
|
2005-07-29 |
2016-06-14 |
Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Use of chk2 kinase inhibitors for cancer treatment
|
EP2324886A1
(de)
|
2005-07-29 |
2011-05-25 |
Concert Pharmaceuticals Inc. |
Neue deuterierte Analoga des Tadalafils
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
US20070128272A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Zerbe Horst G |
Multi-vitamin and mineral supplement
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
EP2586433A1
(de)
*
|
2006-03-17 |
2013-05-01 |
Johns Hopkins University School of Medicine |
N-hydroxylsulfonamidderivate als neue physiologisch nützliche Nytroxyl-Spender
|
US8299052B2
(en)
*
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US8551995B2
(en)
|
2007-01-19 |
2013-10-08 |
Xcovery Holding Company, Llc |
Kinase inhibitor compounds
|
KR101813551B1
(ko)
|
2007-09-26 |
2018-01-02 |
존스 홉킨스 유니버시티 |
신규의 생리적으로 유용한 니트록실 도너로서 n-히드록실술폰아미드 유도체
|
DK2234607T3
(da)
*
|
2007-12-28 |
2011-11-21 |
Acraf |
Formulering med langsom frigivelse på basis af en forbindelse af glykogen og alginat
|
US8318705B2
(en)
|
2008-05-07 |
2012-11-27 |
Cardioxyl Pharmaceuticals, Inc. |
Nitroso compounds as nitroxyl donors and methods of use thereof
|
JP5670325B2
(ja)
|
2008-06-19 |
2015-02-18 |
エックスカバリー ホールディング カンパニー エルエルシー |
キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物
|
CN102239149B
(zh)
|
2008-10-06 |
2015-05-13 |
约翰·霍普金斯大学 |
喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
|
WO2011063339A1
(en)
*
|
2009-11-23 |
2011-05-26 |
Cardioxyl Pharmaceuticals, Inc. |
Nitroxyl donors for the treatment of pulmonary hypertension
|
MX2012006265A
(es)
|
2009-12-03 |
2012-07-25 |
Opko Health Inc |
Formulaciones disacaridas hipersulfatadas.
|
CN102753519B
(zh)
*
|
2009-12-07 |
2015-08-05 |
约翰斯霍普金斯大学 |
二酰基化的羟基胺衍生物
|
US20110144067A1
(en)
*
|
2009-12-07 |
2011-06-16 |
Toscano John P |
N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives
|
US20120082720A1
(en)
*
|
2010-10-05 |
2012-04-05 |
Sam Poon Ang |
Compositions For Treating Chronic Viral Infections
|
US20120082719A1
(en)
*
|
2010-10-05 |
2012-04-05 |
Sam Poon Ang |
Compositions For Treating Chronic Viral Infections
|
CN103298806B
(zh)
|
2010-10-08 |
2015-03-18 |
贝达药业股份有限公司 |
取代的哒嗪羧酰胺化合物
|
SG11201401587QA
(en)
|
2011-10-17 |
2014-07-30 |
Univ Johns Hopkins |
Meldrum 's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
|
WO2014070919A1
(en)
|
2012-11-01 |
2014-05-08 |
The Johns Hopkins University |
Controlled hno release through intramolecular cyclization-elimination
|
NZ748771A
(en)
|
2013-01-18 |
2019-12-20 |
Cardioxyl Pharmaceuticals Inc |
Pharmaceutical compositions comprising nitroxyl donors
|
CN105377292A
(zh)
|
2013-04-07 |
2016-03-02 |
博德研究所 |
用于个性化瘤形成疫苗的组合物和方法
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
KR20230076867A
(ko)
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
WO2015109210A1
(en)
|
2014-01-17 |
2015-07-23 |
Cardioxyl Pharmaceuticals, Inc. |
N-hydroxymethanesulfonamide nitroxyl donors
|
US9464061B2
(en)
|
2014-05-27 |
2016-10-11 |
The Johns Hopkins University |
N-hydroxylamino-barbituric acid derivatives
|
EP3148983A1
(de)
|
2014-05-27 |
2017-04-05 |
The Johns Hopkins University |
N-hydroxylaminobarbitursäure-derivate als nitroxyldonatoren
|
US9682938B2
(en)
|
2014-05-27 |
2017-06-20 |
Cardioxyl Pharmaceuticals, Inc. |
Pyrazolone derivatives as nitroxyl donors
|
WO2016100977A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Methods for profiling the t-cel- receptor repertoire
|
EP3234193B1
(de)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molekulare biomarker für krebsimmuntherapie
|
RU2017126462A
(ru)
|
2014-12-23 |
2019-01-24 |
Церекор, Инк. |
Соединения, композиции и способы
|
JP6913032B2
(ja)
|
2015-05-20 |
2021-08-04 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
共通ネオ抗原
|
AU2016276783B2
(en)
|
2015-06-09 |
2020-07-02 |
Rexahn Pharmaceuticals, Inc. |
Fluorocyclopentenylcytosine uses and processes of preparation
|
KR101592144B1
(ko)
|
2015-06-19 |
2016-02-04 |
고려대학교 산학협력단 |
요오드 캡슐, 이의 제조방법 및 이를 포함하는 소금
|
US10383825B2
(en)
|
2015-08-13 |
2019-08-20 |
Temple University—Of the Commonwealth System of Higher Education |
Calcium alginate dosage formulations, and methods of making and using thereof
|
EP3344250A2
(de)
|
2015-09-04 |
2018-07-11 |
Rexahn Pharmaceuticals, Inc. |
Chinoxalinyl-piperazinamid, verfahren zur verwendung
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
HUE058120T2
(hu)
|
2016-10-03 |
2022-07-28 |
Highlightll Pharmaceutical Hainan Co Ltd |
Új JAK1-szelektív inhibitorok és alkalmazásuk
|
EP3574116A1
(de)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
|
RU2020136057A
(ru)
|
2018-05-04 |
2022-05-04 |
Толлиз |
Лиганды tlr3, которые активируют как эпителиальные, так и миелоидные клетки
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
WO2020215037A1
(en)
|
2019-04-18 |
2020-10-22 |
The Regents Of The University Of Michigan |
Combination with checkpoint inhibitors to treat cancer
|
KR20230029673A
(ko)
|
2020-05-26 |
2023-03-03 |
디오니스 테라퓨틱스, 아이엔씨. |
핵산 인공 미니-프로테옴 라이브러리
|
WO2021248093A1
(en)
|
2020-06-05 |
2021-12-09 |
Henry Ford Health System |
Daclatasvir for use in treating lung and prostate cancer
|
JP2024501995A
(ja)
|
2020-12-22 |
2024-01-17 |
メカニスティク・セラピューティクス・エルエルシー |
Egfr及び/又はpi3k阻害剤としての置換アミノベンジルヘテロアリール化合物
|
WO2022189861A1
(en)
|
2021-03-08 |
2022-09-15 |
Tollys |
Carbohydrate conjugates of tlr3 ligands and uses thereof
|
WO2023076733A1
(en)
|
2021-11-01 |
2023-05-04 |
Dana-Farber Cancer Institute, Inc. |
Biologically selected nucleic acid artificial mini-proteome libraries
|